However an awesome finding on cancer healing research has confirmed that hormone based antitumor drugs can perform tremendously well as an alternative of Chemotherapy in particular cases of cancer.
His research was presented at the European Cancer Congress in Vienna and published in the New England Journal of Medicine.
Using 10,253 women with breast cancer (specifically hormone-receptor positive, HER2 negative), the study was conducted over five years. “In women whose breast cancer scored low on the multigene test, there was outstanding survival with endocrine therapy alone”.
The team also found that premature birth - a major cause of development problems - was more frequent among children born to mothers with cancer, regardless of whether or not they received treatment. Although Doctors are aware that most of these women do not necessarily need chemo but there are no ways to evaluate who can safely skip it.
The study assessed the effectiveness of a genetic test called Oncotype DX, created by Genomic Health, Inc.
Hayes and his colleagues are now testing to see which of these patients benefit from chemotherapy. However, future studies on the tests may help to lower its price along with increased efficiency.
But TAILORx randomly assigned women with an Oncotype Dx recurrence score of less than 11 to just take hormone therapy alone, and skip the chemo. The researchers focused on a group of 129 children exposed to chemotherapy in the latter stages of pregnancy, when the brain is developing. About 94 percent were free of any invasive cancer, including new cancers at other sites or in the opposite breast. Hint - women in the early stage of the disease can choose not to undergo chemotherapy without worrying that they’re going to hurt their chances of getting better.
The test told Puopolo she could avoid chemo, which was a huge relief to her. Although the lymph nodes were not involved, the tumors had other features that indicated chemotherapy should be given, followed by tamoxifen or other endocrine therapy pills. “I really wanted to make the best decision on behalf of my health”, Puopolo said.
Breast cancer survivor Mary Lou Smith, a leader in the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN) who helped design the study, says the findings offer hope for many women with early-stage breast cancer.
“Our results show that fear of cancer treatment is no reason to terminate a pregnancy, that maternal treatment should not be delayed and that chemotherapy can be given”, said Frederic Amant, a professor and gynaecological oncologist at University Hospitals Leuven in Belgium who led the work.
